Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates
Executive Summary
$465m settlement with DOJ to resolve questions about EpiPen's classification is roughly the size of autoinjector's Medicaid and Medicare sales last year; Mylan expects to enter corporate integrity agreement.
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Medicare Part D Drug Price Policies May Offer Financial Trade-Offs
Higher manufacturer discounts required in donut hole under new budget law could offset somewhat by point-of-sale rebates in Part D, which are expected to be included in President Trump's FY 2019 budget proposal.
Medtech And US DoJ: EpiPen, Dermagraft Lead 2017 Payouts To Feds
US DoJ collected more than $1bn in penalties from device manufacturers this year, chiefly on false claims and manufacturing violations. Here is a roundup and sortable table of the payouts.